ALCAM

Across TCGA pan-cancer cohorts, ALCAM mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ALCAM data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ALCAM mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ALCAM expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where ALCAM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.621	0.788	.015	8	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →
LSCC	DFS	Median	II,III,IV	0.451	0.877	.044	1	view →
CCRCC	DFS	Median	All	0.912	0.577	.012	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ALCAM–HNSC (OS)

Open the HNSC breakdown →